why toxic convert.financing?
why don't they have a reputable investment banker?
Why don't they have a deal with big pharma?
not much here- that s why its 8 cents
I lost $$$ in the common. Sold yesterday and bought the bonds. Took the loss. BTW Buying the bonds doesn't trigger the wash sale rule.
HY funds are dumping highly levered oil co. bonds. SD's 8 3/4 % 5 yr. paper is trading at 66 down form 92 just 3 mos. ago. The bonds are still money good with a 19% ytm.
If the stock is worth anything going forward the bonds will trade at par. Even in a BK (doubtful) bondholders get paid before shareholders.
Why own the stock?
Management are nit wits. BMY bought Medarex and CLDX came out of Medarex. Sell to BMY.
Maybe we'll get 18 to 20. This team couldn't find their #$%$ with both hands.
what a bunch of crybaby rookies. Flooding call? What will that do except make you lokk like idiots. When things happen --they happen. Acting like morons won't do anything.
just as many spaghetti benders that came to Ellis Island in the early 1900's
also The PR announcing that NVS would fund P 3 was put out by ARRY to comfort ARRY holders- read it and you'll see that NVS HAD to fund P 3 under the license deal
a few things- NVS hasn't given 162 back YET because the GSK deal hasn't closed. NVS has to pay for 162 phase 3 no matter what. Why give Mekinist up? ts approved- so there's no risk- there's still a risk that 162 may have problems in P 3 . Also it's 2 years away from approval.
the ARRY/NVS deal does in fact limit NVS to only one MEK Inhibitor. NVS gets Mekinist in the GSK purchase. Mekinist is already on the market. NVS will give 162 back.
under the deal with NVS- NVS can have only one MEK inhibitor. They'll give 162 back to ARRY but will still have to pay for the phase 3 trials. ARYY can then relicense the drug to someone else. Home run
google msn money April 16 7 17 pm